methocarbamol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1747	532-03-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methocarbamol glycerylguaiacolate carbamate guaiacol glyceryl ether carbamate guaiphenesin carbamate guaiamar carbamate	A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206) Molecular weight: 241.24 Formula: C11H15NO5 CLOGP: 0.15 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 91.01 ALOGS: -1.76 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methocarbamol
glycerylguaiacolate carbamate
guaiacol glyceryl ether carbamate
guaiphenesin carbamate
guaiamar carbamate

A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)

Molecular weight: 241.24
Formula: C11H15NO5
CLOGP: 0.15
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 91.01
ALOGS: -1.76
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	O
3	g	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 16, 1957	FDA	AUXILIUM PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	114.40	12.86	189	21350	145484	63321999
Necrosis ischaemic	64.85	12.86	20	21519	840	63466643
Contraindicated product administered	61.35	12.86	3	21536	217645	63249838
Pneumonia streptococcal	53.79	12.86	21	21518	1790	63465693
Treatment failure	49.60	12.86	5	21534	199038	63268445
Beta haemolytic streptococcal infection	48.12	12.86	20	21519	2005	63465478
Acquired haemophilia	45.52	12.86	16	21523	1015	63466468
Drug intolerance	45.51	12.86	24	21515	308637	63158846
Maternal exposure during pregnancy	44.65	12.86	10	21529	220052	63247431
Glossodynia	43.28	12.86	5	21534	178871	63288612
Gallbladder polyp	41.71	12.86	14	21525	773	63466710
Systemic lupus erythematosus	41.38	12.86	10	21529	208908	63258575
Spinal operation	39.23	12.86	28	21511	8243	63459240
Surgery	38.63	12.86	54	21485	35858	63431625
Diabetes mellitus inadequate control	35.44	12.86	34	21505	15092	63452391
Fall	34.86	12.86	240	21299	392094	63075389
Infusion related reaction	33.45	12.86	21	21518	245500	63221983
Muscle spasms	32.86	12.86	122	21417	156028	63311455
Multiple drug therapy	31.44	12.86	18	21521	3628	63463855
Depression	31.42	12.86	141	21398	196351	63271132
Intervertebral disc protrusion	30.64	12.86	39	21500	23670	63443813
Wound	30.08	12.86	9	21530	163254	63304229
Anxiety	29.62	12.86	149	21390	217392	63250091
Product dose omission issue	29.49	12.86	157	21382	234156	63233327
Joint swelling	28.39	12.86	42	21497	327624	63139859
Suspected suicide	26.13	12.86	20	21519	6548	63460935
Migraine	25.39	12.86	85	21454	103261	63364222
Drug hypersensitivity	24.63	12.86	185	21354	310502	63156981
Alopecia	24.02	12.86	49	21490	337487	63129996
Amnesia	23.84	12.86	56	21483	55529	63411954
Off label use	23.33	12.86	134	21405	674328	62793155
Lower respiratory tract infection	23.12	12.86	8	21531	132299	63335184
Back disorder	22.54	12.86	23	21516	10994	63456489
Exercise tolerance decreased	22.44	12.86	17	21522	5480	63462003
Pre-existing condition improved	22.15	12.86	20	21519	8224	63459259
Blood pressure inadequately controlled	21.67	12.86	16	21523	4962	63462521
Illness	21.67	12.86	50	21489	49009	63418474
Exposure during pregnancy	21.59	12.86	13	21526	155534	63311949
Respiratory arrest	21.19	12.86	39	21500	32606	63434877
Back pain	20.76	12.86	157	21382	263988	63203495
Therapeutic product effect decreased	20.69	12.86	21	21518	193166	63274317
Exposure via skin contact	20.65	12.86	7	21532	398	63467085
Bronchitis	20.21	12.86	90	21449	124845	63342638
Neutropenia	19.93	12.86	18	21521	174987	63292496
Multiple sclerosis	19.59	12.86	32	21507	24340	63443143
Loss of consciousness	19.04	12.86	85	21454	118036	63349447
Multiple sclerosis relapse	18.82	12.86	47	21492	48431	63419052
Analgesic drug level increased	18.57	12.86	11	21528	2361	63465122
Withdrawal syndrome	18.49	12.86	28	21511	19969	63447514
Hepatic enzyme increased	18.44	12.86	25	21514	202303	63265180
Feeling abnormal	18.35	12.86	99	21440	148293	63319190
Febrile neutropenia	17.74	12.86	9	21530	118440	63349043
Somnolence	17.44	12.86	112	21427	178573	63288910
Discomfort	17.02	12.86	19	21520	167355	63300128
Impaired quality of life	16.75	12.86	22	21517	13761	63453722
Therapy interrupted	16.50	12.86	35	21504	32420	63435063
Cardio-respiratory arrest	16.24	12.86	51	21488	59908	63407575
Thyroiditis chronic	16.14	12.86	3	21536	12	63467471
Attention deficit hyperactivity disorder	15.95	12.86	11	21528	3065	63464418
Road traffic accident	15.81	12.86	37	21502	36595	63430888
Toxicity to various agents	15.67	12.86	140	21399	247110	63220373
Therapy cessation	15.66	12.86	33	21506	30424	63437059
Kidney infection	15.43	12.86	28	21511	23148	63444335
Neck pain	15.27	12.86	55	21484	69263	63398220
Psoriasis	15.09	12.86	64	21475	86893	63380590
Suicidal ideation	15.02	12.86	51	21488	62370	63405113
Rheumatoid arthritis	14.00	12.86	42	21497	253777	63213706
Memory impairment	13.87	12.86	71	21468	104187	63363296
Oesophagitis	13.85	12.86	21	21518	14987	63452496
Pancytopenia	13.59	12.86	8	21531	96925	63370558
Intervertebral disc disorder	13.51	12.86	12	21527	4831	63462652
Obstruction	13.50	12.86	10	21529	3117	63464366
Rib fracture	13.43	12.86	26	21513	22571	63444912
Cardiac failure	13.01	12.86	7	21532	89135	63378348
Malignant neoplasm of spinal cord	12.99	12.86	3	21536	40	63467443

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Respiratory depression	125.57	14.58	68	8998	16177	34931688
Drug dependence	122.55	14.58	77	8989	24140	34923725
Product prescribing error	89.47	14.58	62	9004	22865	34925000
Child abuse	78.89	14.58	19	9047	408	34947457
Epidural lipomatosis	61.88	14.58	19	9047	1035	34946830
Juvenile idiopathic arthritis	50.93	14.58	19	9047	1878	34945987
Victim of child abuse	43.15	14.58	14	9052	913	34946952
Intentional product misuse	28.37	14.58	46	9020	45565	34902300
Phonophobia	27.82	14.58	7	9059	181	34947684
Depression	26.86	14.58	70	8996	97028	34850837
Obesity	26.69	14.58	24	9042	12854	34935011
Back disorder	21.38	14.58	16	9050	6635	34941230
Back pain	19.84	14.58	73	8993	121716	34826149
Spinal operation	19.11	14.58	11	9055	2933	34944932
Drug abuse	18.37	14.58	62	9004	99034	34848831
Serum procollagen type III N-terminal propeptide increased	18.28	14.58	4	9062	55	34947810
Anxiety	18.25	14.58	62	9004	99366	34848499
Memory impairment	17.19	14.58	36	9030	43282	34904583
Subgaleal haematoma	16.22	14.58	4	9062	95	34947770
General physical health deterioration	15.39	14.58	7	9059	128262	34819603
Intervertebral disc degeneration	15.39	14.58	13	9053	6404	34941461
Pancytopenia	15.38	14.58	3	9063	95154	34852711
Pain	14.67	14.58	97	8969	204578	34743287
Post-traumatic neck syndrome	14.60	14.58	4	9062	145	34947720

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	95.80	12.12	220	23524	245547	79475097
Respiratory depression	86.05	12.12	69	23675	27561	79693083
Drug dependence	83.08	12.12	80	23664	40689	79679955
Child abuse	76.18	12.12	19	23725	410	79720234
Necrosis ischaemic	62.75	12.12	20	23724	1070	79719574
Product prescribing error	57.78	12.12	69	23675	44744	79675900
Epidural lipomatosis	56.43	12.12	19	23725	1209	79719435
Beta haemolytic streptococcal infection	49.97	12.12	20	23724	2077	79718567
Pneumonia streptococcal	44.77	12.12	20	23724	2725	79717919
Spinal operation	41.21	12.12	27	23717	7890	79712754
Victim of child abuse	40.87	12.12	14	23730	939	79719705
Gallbladder polyp	40.35	12.12	14	23730	976	79719668
Fall	38.73	12.12	263	23481	487366	79233278
Acquired haemophilia	37.96	12.12	16	23728	1895	79718749
Depression	37.85	12.12	146	23598	216644	79504000
Anxiety	36.00	12.12	158	23586	248354	79472290
Drug intolerance	34.18	12.12	18	23726	264101	79456543
Back disorder	34.11	12.12	28	23716	11550	79709094
Surgery	32.06	12.12	44	23700	32722	79687922
Juvenile idiopathic arthritis	31.73	12.12	19	23725	4744	79715900
Respiratory arrest	31.12	12.12	59	23685	57491	79663153
Contraindicated product administered	30.75	12.12	5	23739	157533	79563111
Neutropenia	28.74	12.12	26	23718	287684	79432960
Intentional product misuse	28.36	12.12	77	23667	95088	79625556
Treatment failure	28.02	12.12	8	23736	170478	79550166
Back pain	25.26	12.12	166	23578	304014	79416630
Infusion related reaction	25.23	12.12	19	23725	230218	79490426
Pancytopenia	25.07	12.12	9	23735	165736	79554908
Intervertebral disc protrusion	25.06	12.12	33	23711	23588	79697056
Multiple drug therapy	23.93	12.12	15	23729	4063	79716581
Intervertebral disc degeneration	23.18	12.12	26	23718	15759	79704885
Drug abuser	23.06	12.12	17	23727	5996	79714648
Thrombocytopenia	23.06	12.12	27	23717	265232	79455412
Exposure via skin contact	22.98	12.12	7	23737	322	79720322
Muscle spasms	22.97	12.12	108	23636	174622	79546022
Diabetes mellitus inadequate control	22.86	12.12	32	23712	24232	79696412
Multiple sclerosis relapse	21.89	12.12	45	23699	46488	79674156
Feeling abnormal	21.37	12.12	99	23645	159100	79561544
Systemic lupus erythematosus	21.21	12.12	5	23739	121144	79599500
Contusion	21.07	12.12	94	23650	148682	79571962
Memory impairment	20.93	12.12	77	23667	111657	79608987
Cardiac failure	20.85	12.12	10	23734	154832	79565812
Glossodynia	20.80	12.12	3	23741	103334	79617310
Suspected suicide	20.13	12.12	20	23724	10556	79710088
Phonophobia	19.89	12.12	7	23737	509	79720135
Maternal exposure during pregnancy	19.67	12.12	8	23736	136530	79584114
Migraine	19.61	12.12	64	23680	87429	79633215
Loss of consciousness	19.36	12.12	100	23644	167843	79552801
Back injury	18.38	12.12	19	23725	10504	79710140
Serum procollagen type III N-terminal propeptide increased	18.23	12.12	4	23740	48	79720596
Pain in extremity	18.20	12.12	177	23567	364361	79356283
General physical health deterioration	18.09	12.12	34	23710	275204	79445440
Road traffic accident	17.97	12.12	40	23704	43624	79677020
Drug hypersensitivity	17.91	12.12	151	23593	298765	79421879
Amnesia	17.77	12.12	50	23694	63007	79657637
Pain	17.73	12.12	301	23443	703501	79017143
Product dose omission issue	17.54	12.12	130	23614	247407	79473237
Therapy cessation	17.28	12.12	36	23708	37526	79683118
Suicidal ideation	17.25	12.12	56	23688	76284	79644360
Cardio-respiratory arrest	17.24	12.12	71	23673	108439	79612205
Analgesic drug level increased	16.93	12.12	11	23733	3167	79717477
Emotional distress	16.88	12.12	37	23707	39932	79680712
Malignant neoplasm progression	16.53	12.12	10	23734	135980	79584664
Wound	16.42	12.12	7	23737	116172	79604472
Blood pressure inadequately controlled	16.26	12.12	14	23730	6163	79714481
Overdose	16.18	12.12	102	23642	184104	79536540
Oesophageal stenosis	16.00	12.12	12	23732	4342	79716302
Interstitial lung disease	15.58	12.12	7	23737	112593	79608051
Joint swelling	15.40	12.12	40	23704	288606	79432038
Obesity	15.39	12.12	33	23711	35092	79685552
Gastrointestinal disorder	14.83	12.12	9	23735	122196	79598448
Febrile neutropenia	14.77	12.12	29	23715	230970	79489674
Psoriasis	14.53	12.12	59	23685	89528	79631116
Bronchitis	14.51	12.12	77	23667	130567	79590077
Off label use	14.50	12.12	187	23557	907028	78813616
Subgaleal haematoma	14.33	12.12	4	23740	135	79720509
Attention deficit hyperactivity disorder	14.16	12.12	10	23734	3299	79717345
Spinal fusion surgery	14.05	12.12	12	23732	5226	79715418
Spinal osteoarthritis	14.02	12.12	21	23723	16906	79703738
Pyrexia	13.97	12.12	132	23612	678577	79042067
Lower respiratory tract infection	13.72	12.12	11	23733	129209	79591435
Neck pain	13.31	12.12	51	23693	75366	79645278
Intervertebral disc displacement	13.24	12.12	5	23739	444	79720200
Therapy interrupted	13.22	12.12	29	23715	31312	79689332
Head injury	12.94	12.12	32	23712	37337	79683307
Therapeutic product effect decreased	12.86	12.12	18	23726	163845	79556799
Intervertebral disc disorder	12.83	12.12	11	23733	4814	79715830
Insomnia	12.69	12.12	120	23624	245050	79475594
Fracture nonunion	12.62	12.12	7	23737	1515	79719129
Hepatic enzyme increased	12.49	12.12	22	23722	182588	79538056
Leukopenia	12.27	12.12	10	23734	116503	79604141
Vision blurred	12.16	12.12	63	23681	105835	79614809

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M03BA03	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
ATC	M03BA53	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
ATC	M03BA73	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D009125	Muscle Relaxants, Central
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:51371	muscle relaxants
FDA PE	N0000175730	Centrally-mediated Muscle Relaxation
FDA EPC	N0000175737	Muscle Relaxant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Spasticity	indication	221360009
Muscle Spasm with Pain	indication
Tetanus Adjunct Treatment	indication
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Gastrointestinal ulcer	contraindication	40845000
Vitamin K deficiency	contraindication	52675005	DOID:11249
Nasal polyp	contraindication	52756005
Acute nephropathy	contraindication	58574008
Factor II deficiency	contraindication	73975000
Reye's syndrome	contraindication	74351001	DOID:14525
Gastrointestinal hemorrhage	contraindication	74474003
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hemophilia	contraindication	90935002
Anemia due to enzyme deficiency	contraindication	111577008
von Willebrand disorder	contraindication	128105004	DOID:12531
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Breastfeeding (mother)	contraindication	413712001
Acute erosive gastritis	contraindication	444926003

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Acute inflammatory and traumatic conditions of the skeletal muscles	Indication
Cats	Reducing muscular spasms	Indication
Dogs	Acute inflammatory and traumatic conditions of the skeletal muscles	Indication
Dogs	Reducing muscular spasms	Indication
Horses	Acute inflammatory and traumatic conditions of the skeletal muscles	Indication
Horses	Reducing muscular spasms	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Robaxin-V Injectable	Kinetic Technologies LLC	1
Robaxin-V Tablets	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN	INHIBITOR	Ki	7.60		IUPHAR	CHEMBL

External reference:

ID	Source
4017879	VUID
N0000146232	NUI
D00402	KEGG_DRUG
4017879	VANDF
C0025659	UMLSCUI
CHEBI:6832	CHEBI
CHEMBL1201117	ChEMBL_ID
DB00423	DRUGBANK_ID
D008721	MESH_DESCRIPTOR_UI
4107	PUBCHEM_CID
6829	IUPHAR_LIGAND_ID
776	INN_ID
125OD7737X	UNII
6845	RXNORM
5075	MMSL
988	MMSL
d00965	MMSL
001669	NDDF
387486000	SNOMEDCT_US
83973001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1290	TABLET	500 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1292	TABLET	750 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0276-0510	TABLET, COATED	1000 mg	ORAL	ANDA	18 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9909	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9909	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9992	INJECTION, SOLUTION	1000 mg	INTRAVENOUS	ANDA	12 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1740	TABLET	500 mg	ORAL	ANDA	23 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1825	INJECTION	100 mg	INTRAMUSCULAR	ANDA	20 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8435	TABLET, FILM COATED	500 mg	ORAL	ANDA	20 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8435	TABLET, FILM COATED	500 mg	ORAL	ANDA	20 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8436	TABLET, FILM COATED	750 mg	ORAL	ANDA	20 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8436	TABLET, FILM COATED	750 mg	ORAL	ANDA	20 sections
ROBAXIN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6103	INJECTION	100 mg	INTRAMUSCULAR	NDA	22 sections
ROBAXIN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6217	INJECTION	100 mg	INTRAMUSCULAR	NDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7057	TABLET	500 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7057	TABLET	500 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7058	TABLET	750 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7058	TABLET	750 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-664	TABLET, FILM COATED	500 mg	ORAL	ANDA	19 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-665	TABLET, FILM COATED	750 mg	ORAL	ANDA	19 sections
Methocarbamol Tablets, USP, 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	10135-722	TABLET, FILM COATED	500 mg	ORAL	ANDA	20 sections
Methocarbamol Tablets, USP, 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	10135-722	TABLET, FILM COATED	500 mg	ORAL	ANDA	20 sections
Methocarbamol Tablets, USP, 750 mg	HUMAN PRESCRIPTION DRUG LABEL	1	10135-723	TABLET, FILM COATED	750 mg	ORAL	ANDA	20 sections
Methocarbamol Tablets, USP, 750 mg	HUMAN PRESCRIPTION DRUG LABEL	1	10135-723	TABLET, FILM COATED	750 mg	ORAL	ANDA	20 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-259	TABLET	750 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-464	TABLET	750 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-622	TABLET	750 mg	ORAL	ANDA	19 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-773	TABLET	500 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-956	TABLET	750 mg	ORAL	ANDA	23 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-147	TABLET	500 mg	ORAL	ANDA	21 sections